Journal
NEUROREPORT
Volume 26, Issue 7, Pages 399-404Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/WNR.0000000000000359
Keywords
neural stem cells; neuropathic pain; sciatic nerve injury; vascular endothelial growth factor
Categories
Funding
- Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea [A120254]
- Yonsei University College of Medicine [6-2014-0021]
Ask authors/readers for more resources
Previously, we determined that vascular endothelial growth factor (VEGF) improves the survival of neural stem cells (NSCs) transplanted into an ischemic environment and effectively enhances angiogenesis. Here, we applied NSCs expressing VEGF (SV-VEGF-NSCs) to treat neuropathic pain. In this study, our goal was to verify the therapeutic effect of SV-VEGF-NSCs by transplanting the cells in a sciatic nerve injury model. We compared the amount of VEGF secreted from DsRed-NSCs (control) or SV-VEGF-NSCs and observed that SV-VEGF-NSCs have a much higher expression level of VEGF. We next investigated whether transplantation with SV-VEGF-NSCs aids functional recovery and pain reduction. We confirmed that transplantation with SV-VEGF-NSCs enhances functional recovery, pain reduction, and remyelination as well as the number of blood vessels compared with the control groups. Our results show that VEGF aids functional recovery and pain reduction in a sciatic nerve injury model. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available